CRVS - Company ID 0001626971
The table below shows Corvus Pharmaceuticals, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$10.37M | -$8.26M | -$5.16M | -$8.11M | -$6.42M | -$8.79M |
| Capital expenditure | $91.00K | $36.00K | - | $34.00K | - | - |
| Investing cash flow | -$144.85M | $4.24M | -$7.00K | $4.60M | -$25.57M | $4.85M |
| Dividends paid | - | - | - | - |
Corvus Pharmaceuticals, Inc. reported operating cash flow of -$32.80M for fiscal year 2025. That is down 29.0% from -$25.42M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow declined from -$27.86M (FY 2016) to -$32.80M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $190.75M | $279.00K | - | $4.00K | - | $32.59M |